{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [],
      "ArmGroupInterventionName": [],
      "ArmGroupLabel": [],
      "ArmGroupType": [],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00361049"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "RATIONALE: Donor mesenchymal stem cell infusion may be an effective treatment for acute or chronic graft-versus-host disease caused by a donor stem cell transplant.\n\nPURPOSE: This phase I trial is studying the side effects and best dose of donor mesenchymal stem cells in treating patients with acute or chronic graft-versus-host disease after undergoing a donor stem cell transplant."
      ],
      "BriefTitle": [
            "Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "NIH"
      ],
      "CollaboratorName": [
            "National Cancer Institute (NCI)"
      ],
      "CompletionDate": [
            "November 2010"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Cancer"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC04",
            "BC14",
            "BC15",
            "BC20",
            "All",
            "BC17",
            "BC23",
            "BC16",
            "BXS",
            "BC19",
            "BC01",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Neoplasms",
            "Heart and Blood Diseases",
            "Blood and Lymph Conditions",
            "Immune System Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases",
            "Symptoms and General Pathology",
            "Diseases and Abnormalities at or Before Birth",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Gland and Hormone Related Diseases",
            "Infections",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft Versus Host Disease",
            "Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M11210",
            "M26741",
            "M4372",
            "M10097",
            "M26738",
            "M10103",
            "M15507",
            "M12",
            "M17268",
            "M27465",
            "M10107",
            "M17279",
            "M10372",
            "M1704",
            "M13316",
            "M11297",
            "M8341",
            "M11459",
            "M4473",
            "M17980",
            "M8903",
            "M17983",
            "M10374",
            "M21460",
            "M11543",
            "M11301",
            "M10373",
            "M17284",
            "M26859",
            "M19707",
            "M381",
            "M17982",
            "M17275",
            "M4185",
            "M15658",
            "M17277",
            "M17276",
            "M16232",
            "M17278",
            "M9352",
            "T3947",
            "T175",
            "T3533",
            "T640",
            "T1308",
            "T4705",
            "T3995",
            "T182",
            "T188",
            "T3543",
            "T4352",
            "T4354",
            "T3993",
            "T2832",
            "T1303",
            "T2817",
            "T1866",
            "T892",
            "T3601",
            "T2475",
            "T4085",
            "T1311",
            "T3994",
            "T2361",
            "T1310",
            "T3174",
            "T3612",
            "T4586",
            "T3539",
            "T1309",
            "T170",
            "T2482",
            "T5603",
            "T1312"
      ],
      "ConditionBrowseLeafName": [
            "Multiple Myeloma",
            "Neoplasms, Plasma Cell",
            "Breast Neoplasms",
            "Leukemia",
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "Leukemia, Lymphoid",
            "Syndrome",
            "Congenital Abnormalities",
            "Leukemia, Lymphocytic, Chronic, B-Cell",
            "Primary Myelofibrosis",
            "Leukemia, Myeloid",
            "Leukemia, Myeloid, Acute",
            "Lymphoma",
            "Carcinoma, Ovarian Epithelial",
            "Preleukemia",
            "Myelodysplastic Syndromes",
            "Graft vs Host Disease",
            "Neoplasm Metastasis",
            "Burkitt Lymphoma",
            "Lymphoma, B-Cell",
            "Hodgkin Disease",
            "Lymphoma, Large B-Cell, Diffuse",
            "Lymphoma, Non-Hodgkin",
            "Lymphoma, Mantle-Cell",
            "Neuroblastoma",
            "Myeloproliferative Disorders",
            "Lymphoma, Follicular",
            "Leukemia, Myelomonocytic, Chronic",
            "Leukemia, Myelomonocytic, Juvenile",
            "Lymphoma, B-Cell, Marginal Zone",
            "Plasmablastic Lymphoma",
            "Lymphoma, Large-Cell, Immunoblastic",
            "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
            "Blast Crisis",
            "Testicular Neoplasms",
            "Leukemia, Myeloid, Chronic-Phase",
            "Leukemia, Myeloid, Accelerated Phase",
            "Trophoblastic Neoplasms",
            "Leukemia, Neutrophilic, Chronic",
            "Immune System Diseases",
            "Multiple Myeloma",
            "Acute Lymphoblastic Leukemia",
            "Lymphoblastic Lymphoma",
            "B-cell Lymphoma",
            "Chronic Lymphocytic Leukemia",
            "Primary Myelofibrosis",
            "Myeloid Leukemia",
            "Acute Myeloid Leukemia",
            "Acute Non Lymphoblastic Leukemia",
            "Lymphosarcoma",
            "Ovarian Cancer",
            "Ovarian Epithelial Cancer",
            "Myelodysplastic Syndromes",
            "Homologous Wasting Disease",
            "Chronic Graft Versus Host Disease",
            "Hodgkin Lymphoma",
            "Diffuse Large B-Cell Lymphoma",
            "Burkitt Lymphoma",
            "Mantle Cell Lymphoma",
            "Germ Cells Tumors",
            "Neuroblastoma",
            "Chronic Myeloproliferative Disorders",
            "Myelodysplastic/myeloproliferative Disease",
            "Follicular Lymphoma",
            "Chronic Myelomonocytic Leukemia",
            "Juvenile Myelomonocytic Leukemia",
            "Marginal Zone Lymphoma",
            "Plasmablastic Lymphoma",
            "Lymphoma, Large-cell, Immunoblastic",
            "Chronic Myeloid Leukemia",
            "Acute Graft Versus Host Disease",
            "Gestational Trophoblastic Tumor",
            "Testicular Germ Cell Tumor",
            "Chronic Neutrophilic Leukemia"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "OBJECTIVES:\n\nPrimary\n\nDetermine the safety of donor mesenchymal stem cell (MSC) infusion in patients with acute or extensive chronic graft-vs-host disease (GVHD) after undergoing HLA-identical sibling donor stem cell transplant.\n\nSecondary\n\nDescribe the rates of complete and partial resolution of GVHD when MSCs are used in addition to the standard GVHD therapy.\nDetermine inflammatory cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in blood of patients with acute GVHD prior to therapy and at 7 and 14 days post-MSC therapy.\nDetermine if donor MSCs engraft in tissues inflamed by GVHD in patients who have undergone gender-mismatched transplantation.\n\nOUTLINE: This is a multicenter, dose-escalation study of donor mesenchymal stem cells (MSC).\n\nWithin 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.\n\nCohorts of 3-6 patients receive escalating doses of donor MSCs until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\nBlood samples are obtained periodically and examined by immunoenzyme techniques for mixed lymphocyte reaction (as a surrogate marker for alloreactivity) and cytokine levels (TH1 [i.e., interleukin (IL)-2 and interferon-gamma], TH2 [i.e., IL-10 and IL-4], and inflammatory cytokines [i.e., tumor necrosis factor-alpha and IL-1]). Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.\n\nAfter completion of study treatment, patients are followed periodically for 1 year.\n\nPROJECTED ACCRUAL: A total of 24 patients will be accrued for this study."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "DISEASE CHARACTERISTICS:\n\nDeveloped acute graft-vs-host disease (GVHD) of clinical grade II-IV or extensive chronic GVHD after undergoing HLA-identical sibling donor hematopoietic stem cell transplant for any indication, malignant or nonmalignant\n\nRequires systemic immunosuppressive therapy with systemic corticosteroids (methylprednisone dose 2 mg/kg/day or equivalent) and concurrent cyclosporine or tacrolimus\nMay have been enrolled on an institutional allogeneic stem cell transplant protocol using either ablative or nonmyeloablative preparative regimens\nNo evidence of relapsed or progressive malignant disease at the time of GVHD\n\nPATIENT CHARACTERISTICS:\n\nNot pregnant\nNegative pregnancy test\nCreatinine clearance \u2265 20 mL/min\nOxygen saturation \u2265 90% on room air\nNo severe or symptomatic restrictive or obstructive lung disease or respiratory failure requiring ventilator support\nNo uncontrolled hypertension or congestive heart failure, active angina pectoris requiring the use of nitrates, myocardial infarction within the past 6 months, or major ventricular arrhythmia or cardiac failure requiring active treatment\nNo significant organ dysfunction\n\nNo active severe infections, including sepsis, pneumonia with hypoxemia, persistent bacteremia, or meningitis\n\nFever without a source is allowed\n\nPRIOR CONCURRENT THERAPY:\n\nSee Disease Characteristics"
      ],
      "EnrollmentCount": [
            "49"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ARhu",
            "Derm",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M18113",
            "M5882"
      ],
      "InterventionBrowseLeafName": [
            "Cyclosporine",
            "Cyclosporins"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.",
            "Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.",
            "Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.",
            "Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.",
            "Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.",
            "Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.",
            "Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "graft versus host disease prophylaxis/therapy",
            "fluorescence in situ hybridization",
            "immunoenzyme technique",
            "immunohistochemistry staining method",
            "laboratory biomarker analysis",
            "in vitro-treated bone marrow transplantation",
            "management of therapy complications"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Genetic",
            "Other",
            "Other",
            "Other",
            "Procedure",
            "Procedure"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "graft versus host disease",
            "unspecified adult solid tumor, protocol specific",
            "adult acute myeloid leukemia with 11q23 (MLL) abnormalities",
            "adult acute myeloid leukemia with inv(16)(p13;q22)",
            "adult acute myeloid leukemia with t(15;17)(q22;q12)",
            "adult acute myeloid leukemia with t(16;16)(p13;q22)",
            "adult acute myeloid leukemia with t(8;21)(q22;q22)",
            "accelerated phase chronic myelogenous leukemia",
            "adult acute lymphoblastic leukemia in remission",
            "adult acute myeloid leukemia in remission",
            "atypical chronic myeloid leukemia",
            "blastic phase chronic myelogenous leukemia",
            "chronic eosinophilic leukemia",
            "primary myelofibrosis",
            "chronic myelomonocytic leukemia",
            "chronic neutrophilic leukemia",
            "chronic phase chronic myelogenous leukemia",
            "de novo myelodysplastic syndromes",
            "disseminated neuroblastoma",
            "extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue",
            "myelodysplastic/myeloproliferative disease, unclassifiable",
            "nodal marginal zone B-cell lymphoma",
            "noncontiguous stage II adult Burkitt lymphoma",
            "noncontiguous stage II adult diffuse large cell lymphoma",
            "noncontiguous stage II adult diffuse mixed cell lymphoma",
            "noncontiguous stage II adult diffuse small cleaved cell lymphoma",
            "noncontiguous stage II adult immunoblastic large cell lymphoma",
            "noncontiguous stage II adult lymphoblastic lymphoma",
            "noncontiguous stage II grade 1 follicular lymphoma",
            "noncontiguous stage II grade 2 follicular lymphoma",
            "noncontiguous stage II grade 3 follicular lymphoma",
            "noncontiguous stage II mantle cell lymphoma",
            "noncontiguous stage II marginal zone lymphoma",
            "noncontiguous stage II small lymphocytic lymphoma",
            "poor prognosis metastatic gestational trophoblastic tumor",
            "previously treated myelodysplastic syndromes",
            "secondary acute myeloid leukemia",
            "secondary myelodysplastic syndromes",
            "splenic marginal zone lymphoma",
            "stage I multiple myeloma",
            "stage II multiple myeloma",
            "stage II ovarian epithelial cancer",
            "stage III adult Burkitt lymphoma",
            "stage III adult Hodgkin lymphoma",
            "stage III adult diffuse large cell lymphoma",
            "stage III adult diffuse mixed cell lymphoma",
            "stage III adult diffuse small cleaved cell lymphoma",
            "stage III adult immunoblastic large cell lymphoma",
            "stage III adult lymphoblastic lymphoma",
            "stage III chronic lymphocytic leukemia",
            "stage III grade 1 follicular lymphoma",
            "stage III grade 2 follicular lymphoma",
            "stage III grade 3 follicular lymphoma",
            "stage III mantle cell lymphoma",
            "stage III marginal zone lymphoma",
            "stage III multiple myeloma",
            "stage III ovarian epithelial cancer",
            "stage III small lymphocytic lymphoma",
            "stage III malignant testicular germ cell tumor",
            "stage IIIA breast cancer",
            "stage IIIB breast cancer",
            "stage IIIC breast cancer",
            "stage IV adult Burkitt lymphoma",
            "stage IV adult Hodgkin lymphoma",
            "stage IV adult diffuse large cell lymphoma",
            "stage IV adult diffuse mixed cell lymphoma",
            "stage IV adult diffuse small cleaved cell lymphoma",
            "stage IV adult immunoblastic large cell lymphoma",
            "stage IV adult lymphoblastic lymphoma",
            "stage IV breast cancer",
            "stage IV chronic lymphocytic leukemia",
            "stage IV grade 1 follicular lymphoma",
            "stage IV grade 2 follicular lymphoma",
            "stage IV grade 3 follicular lymphoma",
            "stage IV mantle cell lymphoma",
            "stage IV marginal zone lymphoma",
            "stage IV ovarian epithelial cancer",
            "stage IV small lymphocytic lymphoma"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 5, 2010"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "November 4, 2010"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Case Comprehensive Cancer Center"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Cleveland",
            "Cleveland",
            "Cleveland",
            "Cleveland",
            "Cleveland",
            "Cleveland",
            "Cleveland",
            "Cleveland"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "Geauga Regional Hospital",
            "Lake/University Ireland Cancer Center",
            "Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center",
            "University Suburban Health Center",
            "UHHS Chagrin Highlands Medical Center",
            "Southwest General Health Center",
            "UHHS Westlake Medical Center",
            "Mercy Cancer Center at Mercy Medical Center"
      ],
      "LocationState": [
            "Ohio",
            "Ohio",
            "Ohio",
            "Ohio",
            "Ohio",
            "Ohio",
            "Ohio",
            "Ohio"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "44024",
            "44060",
            "44106-5065",
            "44121",
            "44122",
            "44130",
            "44145",
            "44708"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Case Comprehensive Cancer Center"
      ],
      "OrgStudyId": [
            "CWRU3Y03"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center"
      ],
      "OverallOfficialName": [
            "Hillard M. Lazarus, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "June 2009"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Safety"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Monitored for 6 hours for infusion related toxicity. Temperature, blood pressure, pulse and O2 saturation will be measured at baseline and every 10 minutes x 2, every 30 minutes x 2, and every hour x 3."
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [
            "Hillard M. Lazarus, M.D."
      ],
      "ResponsiblePartyOldOrganization": [
            "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
      ],
      "ResponsiblePartyType": [],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "P30CA043703",
            "CASE-CWRU-3Y03"
      ],
      "SecondaryIdDomain": [
            "Case Comprehensive Cancer Center"
      ],
      "SecondaryIdLink": [
            "https://reporter.nih.gov/quickSearch/P30CA043703"
      ],
      "SecondaryIdType": [
            "U.S. NIH Grant/Contract",
            "Other Identifier"
      ],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Complete and partial resolution of graft-vs-host disease (GVHD)",
            "Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.",
            "Pre-transplant, at diagnosis, 7 and 14 days after MSC infusion"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "September 2004"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "November 2010"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "August 7, 2006"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "August 3, 2006"
      ],
      "StudyFirstSubmitQCDate": [
            "August 3, 2006"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}